Actuate Therapeutics, Inc. announced that their Phase 2 open-label single arm study of elraglusib (9-ING-41) plus gemcitabine/nab-paclitaxel treatment met...
Read moreActuate Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for 9-ING-41 for...
Read moreActuate Therapeutics, Inc. announced enrollment of the first patients with first-line advanced pancreatic cancer in a phase 2 study...
Read moreActuate Therapeutics, Inc. has raised an additional $6.5M in a Series B-3 financing round led by Bios Partners with...
Read moreWe are delighted to announce that Actuate Therapeutics is the latest company to join the Kairos portfolio. Founded in...
Read more